FULC
Fulcrum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.77
+0.80%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.76
From 52W high−74.18%
Volume776313.00
Market cap$287.96M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.76
From 52W high
−74.18%
Volume
776313.00
Market cap
$287.96M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
53.9
MomentumView details →
1D Return
+0.80%
YTD Return
−66.79%
SummaryUpdated Jun 1, 2026
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in July 2019 and focuses on developing treatments for genetically defined rare diseases with high unmet medical need. Fulcrum has evolved from pursuing multiple therapeutic programs to concentrating primarily on <b>pociredir</b> for sickle cell disease, following the discontinuation of its lead program <b>losmapimod</b> for facioscapulohumeral muscular dystrophy (FSHD) in 2024 after Phase 3 trial results failed to meet endpoints.
Similar companies
Latest newsMore news →
Kaplan Fox & Kilsheimer LLP announced that it is investigating potential securities violations by Fulcrum Therapeutics, Inc.29d agoKaplan Fox & Kilsheimer LLP announced on October 2, 2026 that it is investigating Fulcrum Therapeutics, Inc. for possible securities law violations.33d agoKaplan Fox & Kilsheimer LLP broadened its investigation into potential securities law violations by Fulcrum Therapeutics, Inc.43d ago